BioCryst Pharmaceuticals Inc (MEX:BCRX)
MXN 155 0 (0%) Market Cap: 32.99 Bil Enterprise Value: 42.75 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

BioCryst Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 04:40PM GMT
Release Date Price: MXN148
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. My name is Jess Fye. I'm one of the Senior Biotech Analysts at JPMorgan. And we're continuing the 2021 Healthcare Conference today with BioCryst. This year instead of going across the hall to the breakout room, you can use that blue, ask a question button to submit questions to the portal. They'll pop up for me, and I can ask management those questions during our Q&A session after the presentation.

But with that out of the way, let me turn it over to BioCryst's CEO, Jon Stonehouse.

Jon P. Stonehouse
BioCryst Pharmaceuticals, Inc. - CEO, President & Director

Thanks, Jess, and thanks for inviting us to this year's JPMorgan Healthcare Conference. I'm about to make some forward-looking statements, and I want to remind you that those have risks associated with them, and you can find our risk factors listed on our website.

What I'm about to tell you is a story about a small company with a big dream, and this dream recently became a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot